Technical Analysis for BHVN - Biohaven Pharmaceutical Holding Company Ltd.

Grade Last Price % Change Price Change
C 57.02 1.30% 0.73
BHVN closed up 1.3 percent on Wednesday, March 27, 2024, on 69 percent of normal volume.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Gilligan's Island Sell Setup Bearish Swing Setup -59.27%
Crossed Above 20 DMA Bullish -59.27%
Crossed Above 200 DMA Bullish -59.27%
Crossed Above 50 DMA Bullish -59.27%
MACD Bullish Signal Line Cross Bullish -59.27%
New Uptrend Bullish -59.27%
Pocket Pivot Bullish Swing Setup -59.27%
Volume Surge Other -59.27%
NR7 Range Contraction -59.27%
Narrow Range Bar Range Contraction -59.27%

   Recent Intraday Alerts

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Biohaven Pharmaceutical Holding Company Ltd. Description

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Neuroscience Organic Compounds Chemical Compounds Neurodegenerative Diseases Glutamate Neurotransmitters N Methyl D Aspartic Acid Riluzole

Is BHVN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 62.21
52 Week Low 12.35
Average Volume 1,203,559
200-Day Moving Average 32.84
50-Day Moving Average 50.44
20-Day Moving Average 56.37
10-Day Moving Average 56.68
Average True Range 3.24
RSI (14) 57.98
ADX 31.76
+DI 29.25
-DI 16.05
Chandelier Exit (Long, 3 ATRs) 52.48
Chandelier Exit (Short, 3 ATRs) 55.58
Upper Bollinger Bands 61.98
Lower Bollinger Band 50.76
Percent B (%b) 0.56
BandWidth 19.91
MACD Line 1.89
MACD Signal Line 2.37
MACD Histogram -0.4799
Fundamentals Value
Market Cap 4.57 Billion
Num Shares 80.2 Million
EPS -7.23
Price-to-Earnings (P/E) Ratio -7.89
Price-to-Sales 0.00
Price-to-Book 13.43
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 61.30
Resistance 3 (R3) 60.84 58.95 60.58
Resistance 2 (R2) 58.95 57.86 59.18 60.34
Resistance 1 (R1) 57.99 57.19 58.47 58.45 60.11
Pivot Point 56.10 56.10 56.35 56.33 56.10
Support 1 (S1) 55.14 55.01 55.62 55.60 53.93
Support 2 (S2) 53.25 54.34 53.48 53.70
Support 3 (S3) 52.29 53.25 53.46
Support 4 (S4) 52.75